Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer

Ivana Bratić Hench, Jürgen Hench, Markus Tolnay, Ivana Bratić Hench, Jürgen Hench, Markus Tolnay

Abstract

Examination of tumor molecular characteristics by liquid biopsy is likely to greatly influence personalized cancer patient management. Analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived exosomes, all collectively referred to as "liquid biopsies," are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real time. We review the literature concerning the examination of ctDNA and CTC in a diagnostic setting, evaluating their prognostic, predictive, and monitoring capabilities. We discuss the advantages and limitations of various leading ctDNA/CTC analysis technologies. Finally, guided by the results of clinical trials, we discuss the readiness of cell-free DNA and CTC as routine biomarkers in the context of various common types of neoplastic disease. At this moment, one cannot conclude whether or not liquid biopsy will become a mainstay in oncology practice.

Keywords: blood; cancer; cell-free DNA; circulating tumor cell; ctDNA; liquid biopsy; screening.

References

    1. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev (1999) 18:65–73.10.1023/A:1006260319913
    1. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 102:16368–73.10.1073/pnas.0507904102
    1. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 497:108–12.10.1038/nature12065
    1. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 6:224ra24.10.1126/scitranslmed.3007094
    1. Murtaza M, Dawson S-J, Pogrebniak K, Rueda OM, Provenzano E, Grant J, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun (2015) 6:8760.10.1038/ncomms9760
    1. Chan KCA, Jiang P, Zheng YWL, Liao GJW, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2013) 59:211–24.10.1373/clinchem.2012.196014
    1. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol (2014) 25:1729–35.10.1093/annonc/mdu239
    1. Sun K, Jiang P, Chan KCA, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A (2015) 112:E5503–12.10.1073/pnas.1508736112
    1. Stroun M, Lyautey J, Lederrey C, Mulcahy HE, Anker P. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? Ann N Y Acad Sci (2001) 945:258–64.10.1111/j.1749-6632.2001.tb03894.x
    1. Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VW-S, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 112:E1317–25.10.1073/pnas.1500076112
    1. Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol (2014) 8:927–41.10.1016/j.molonc.2014.02.005
    1. Jiang P, Lo YMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet (2016) 32:360–71.10.1016/j.tig.2016.03.009
    1. Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther (2012) 12(Suppl 1):S209–15.10.1517/14712598.2012.688023
    1. Rykova EY, Morozkin ES, Ponomaryova AA, Loseva EM, Zaporozhchenko IA, Cherdyntseva NV, et al. Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and content. Expert Opin Biol Ther (2012) 12(Suppl 1):S141–53.10.1517/14712598.2012.673577
    1. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch R-D, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 61:1659–65.
    1. Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res (2014) 16:421.10.1186/s13058-014-0421-y
    1. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell (2016) 164:57–68.10.1016/j.cell.2015.11.050
    1. García-Olmo DC, Ruiz-Piqueras R, García-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol (2004) 19:575–83.10.14670/HH-19.575
    1. Chen Z, Fadiel A, Naftolin F, Eichenbaum KD, Xia Y. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses (2005) 65:956–61.10.1016/j.mehy.2005.04.042
    1. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 313:139–42.10.1016/S0009-8981(01)00665-9
    1. Anker P, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res (1975) 35:2375–82.
    1. Wang W, Kong P, Ma G, Li L, Zhu J, Xia T, et al. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget (2017) 8:43180.10.18632/oncotarget.17858
    1. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 37:646–50.
    1. van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem (2010) 43:26–36.10.1016/j.clinbiochem.2009.08.027
    1. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet (2007) 276:327–31.10.1007/s00404-007-0345-1
    1. Frank MO. Circulating cell-free DNA differentiates severity of inflammation. Biol Res Nurs (2016) 18:477–88.10.1177/1099800416642571
    1. Tug S, Helmig S, Ricarda Deichmann E, Schmeier-Jürchott A, Wagner E, Zimmermann T, et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev (2015) 21:164–73.
    1. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res (2010) 38:6159–75.10.1093/nar/gkq421
    1. Yu SCY, Lee SWY, Jiang P, Leung TY, Chan KCA, Chiu RWK, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem (2013) 59:1228–37.10.1373/clinchem.2013.203679
    1. Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev (2017) 42:14–21.10.1016/j.gde.2016.12.003
    1. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker – a critical appraisal of the literature. Clin Chim Acta (2010) 411:1611–24.10.1016/j.cca.2010.07.032
    1. Swinkels DW, Wiegerinck E, Steegers EA, de Kok JB. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem (2003) 49:525–6.10.1373/49.3.525
    1. Chan KCA, Yeung S-W, Lui W-B, Rainer TH, Lo YMD. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem (2005) 51:781–4.10.1373/clinchem.2004.046219
    1. Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res (2017) 23:2471–7.10.1158/1078-0432.CCR-16-1691
    1. Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, et al. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas external quality assessment experience. Clin Chem Lab Med (2015) 53:1935–42.10.1515/cclm-2014-1161
    1. Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, Duda A, Gabor M, Eichner R, et al. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med (2017) 56(2):220–8.10.1515/cclm-2017-0283
    1. Thijssen MA, Swinkels DW, Ruers TJM, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res (2002) 22:421–5.
    1. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem (2003) 49:1028–9.10.1373/49.6.1028
    1. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion (2001) 41:276–82.10.1046/j.1537-2995.2001.41020276.x
    1. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non–small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol (2004) 22:4157–64.10.1200/JCO.2004.11.123
    1. Perakis S, Auer M, Belic J, Heitzer E. Advances in circulating tumor DNA analysis. Advances in Clinical Chemistry. Elsevier; (2017). p. 73–153. Available from:
    1. Thelwell N, Millington S, Solinas A, Booth J, Brown T. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res (2000) 28:3752–61.10.1093/nar/28.19.3752
    1. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib: monitoring EGFR Mutations in Plasma DNA. Cancer (2014) 120:3896–901.10.1002/cncr.28964
    1. Jenkins S, Yang JC-H, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol (2017) 12:1061–70.10.1016/j.jtho.2017.04.003
    1. Qin L, Zhong W, Zhang L, Li L, Wang M. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) (2011) 124:887–91.
    1. Wang W, Song Z, Zhang Y. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med (2016) 6(1):154–62.10.1002/cam4.978
    1. Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 20:548–54.10.1038/nm.3519
    1. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med (2008) 14:985–90.10.1038/nm.1789
    1. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 20:1698–705.10.1158/1078-0432.CCR-13-2482
    1. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 20:2643–50.10.1158/1078-0432.CCR-13-2933
    1. Klevebring D, Neiman M, Sundling S, Eriksson L, Darai Ramqvist E, Celebioglu F, et al. Evaluation of exome sequencing to estimate tumor burden in plasma. PLoS One (2014) 9:e104417.10.1371/journal.pone.0104417
    1. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 108:9530–5.10.1073/pnas.1105422108
    1. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 34:547–55.10.1038/nbt.3520
    1. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med (2017) 9:eaan2415.10.1126/scitranslmed.aan2415
    1. Leung F, Kulasingam V, Diamandis EP, Hoon DSB, Kinzler K, Pantel K, et al. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem (2016) 62:1054–60.10.1373/clinchem.2016.260331
    1. Xu S, Lou F, Wu Y, Sun D-Q, Zhang J-B, Chen W, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett (2016) 370:324–31.10.1016/j.canlet.2015.11.005
    1. Vanni I, Coco S, Truini A, Rusmini M, Dal Bello M, Alama A, et al. Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by Ion Torrent PGMTM platform. Int J Mol Sci (2015) 16:28765–82.10.3390/ijms161226129
    1. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res (2014) 20:4613–24.10.1158/1078-0432.CCR-13-3063
    1. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids (2013) 2:e109.10.1038/mtna.2013.28
    1. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 4:162ra154.10.1126/scitranslmed.3004742
    1. Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, et al. Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients. PLoS One (2016) 11:e0161012.10.1371/journal.pone.0161012
    1. Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol (2017) 3:996–8.10.1001/jamaoncol.2016.4983
    1. Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 32:1317–23.10.1200/JCO.2013.52.4298
    1. Oshiro C, Kagara N, Naoi Y, Shimoda M, Shimomura A, Maruyama N, et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat (2015) 150:299–307.10.1007/s10549-015-3322-6
    1. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, et al. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci (2015) 106:1582–9.10.1111/cas.12813
    1. Chen Y-H, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer (2017) 3:24.10.1038/s41523-017-0028-4
    1. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 7:302ra133.10.1126/scitranslmed.aab0021
    1. Shan M, Yin H, Li J, Li X, Wang D, Su Y, et al. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget (2016) 7:18485.10.18632/oncotarget.7608
    1. Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, et al. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing. Tumor Biol (2016) 37(10):13111–9.10.1007/s13277-016-5190-z
    1. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (2012) 22:220–31.10.1101/gr.123497.111
    1. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 18:3462–9.10.1158/1078-0432.CCR-11-2696
    1. Madic J, Kiialainen A, Bidard F-C, Birzele F, Ramey G, Leroy Q, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients: ctDNA and CTC in metastatic triple negative breast cancer. Int J Cancer (2015) 136:2158–65.10.1002/ijc.29265
    1. Liang DH, Ensor JE, Liu Z, Patel A, Patel TA, Chang JC, et al. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat (2016) 155:139–49.10.1007/s10549-015-3635-5
    1. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 368:1199–209.10.1056/NEJMoa1213261
    1. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang M-HE, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med (2015) 7:1034–47.10.15252/emmm.201404913
    1. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem (2015) 61:974–82.10.1373/clinchem.2015.238717
    1. Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res (2016) 22:993–9.10.1158/1078-0432.CCR-15-0943
    1. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 106:dju066.10.1093/jnci/dju066
    1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 351:781–91.10.1056/NEJMoa040766
    1. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol (2014) 32:3483–9.10.1200/JCO.2014.56.2561
    1. Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch SystemTM and AdnaTest BreastTM in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 14:R118.10.1186/bcr3243
    1. Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol (2015) 9:749–57.10.1016/j.molonc.2014.12.001
    1. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 101:9393–8.10.1073/pnas.0402993101
    1. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol (2012) 23:1744–50.10.1093/annonc/mds020
    1. Pierga J-Y, Bidard F-C, Cropet C, Tresca P, Dalenc F, Romieu G, et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann Oncol (2013) 24:2999–3004.10.1093/annonc/mdt348
    1. Guo N, Lou F, Ma Y, Li J, Yang B, Chen W, et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep (2016) 6:33519.10.1038/srep33519
    1. Chen K-Z, Lou F, Yang F, Zhang J-B, Ye H, Chen W, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep (2016) 6:31985.10.1038/srep31985
    1. Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol (2015) 1:149–57.10.1001/jamaoncol.2014.257
    1. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett (2011) 303:21–8.10.1016/j.canlet.2010.12.011
    1. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 61:4675–8.
    1. Tissot C, Toffart A-C, Villar S, Souquet P-J, Merle P, Moro-Sibilot D, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J (2015) 46:1773–80.10.1183/13993003.00676-2015
    1. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res (2016) 22:5772–82.10.1158/1078-0432.CCR-16-1231
    1. Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med (2016) 13:e1002199.10.1371/journal.pmed.1002199
    1. Nygaard AD, Holdgaard PC, Spindler K-LG, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer (2014) 110:363–8.10.1038/bjc.2013.705
    1. Fournié GJ, Courtin J-P, Laval F, Chalé J-J, Pourrat JP, Pujazon M-C, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett (1995) 91:221–7.10.1016/0304-3835(95)03742-F
    1. Yao Y, Liu J, Li L, Yuan Y, Nan K, Wu X, et al. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget (2017) 8:2130–40.10.18632/oncotarget.12883
    1. Nygaard AD, Spindler K-LG, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer (2013) 79:312–7.10.1016/j.lungcan.2012.11.016
    1. Camps C, Sirera R, Bremnes R, Blasco A, Sancho E, Bayo P, et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer (2005) 50:339–46.10.1016/j.lungcan.2005.06.007
    1. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 17:7808–15.10.1158/1078-0432.CCR-11-1712
    1. Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res (2016) 22:1103–10.10.1158/1078-0432.CCR-15-1031
    1. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol (2016) 34:3375–82.10.1200/JCO.2016.66.7162
    1. Wang Z, Chen R, Wang S, Zhong J, Wu M, Zhao J, et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One (2014) 9:e110780.10.1371/journal.pone.0110780
    1. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature (2017) 545:446–51.10.1038/nature22364
    1. Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol (2011) 29:1556–63.10.1200/JCO.2010.28.7045
    1. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res (2011) 17:827–35.10.1158/1078-0432.CCR-10-0445
    1. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 359:366–77.10.1056/NEJMoa0800668
    1. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud J-M, Padovani B, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One (2014) 9:e111597.10.1371/journal.pone.0111597
    1. Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 9:e103883.10.1371/journal.pone.0103883
    1. Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med (2016) 23:114–9.10.1038/nm.4239
    1. Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori (2014) 100:115–21.10.1700/1491.16389
    1. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst (2000) 92:918–23.10.1093/jnci/92.11.918
    1. Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci (2006) 1075:185–90.10.1196/annals.1368.025
    1. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett (2008) 263:170–81.10.1016/j.canlet.2008.03.021
    1. Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut (2016) 65:625–34.10.1136/gutjnl-2014-308859
    1. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res (2006) 12:6985–8.10.1158/1078-0432.CCR-06-1931
    1. Sato KA, Hachiya T, Iwaya T, Kume K, Matsuo T, Kawasaki K, et al. Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. PLoS One (2016) 11:e0146275.10.1371/journal.pone.0146275
    1. Spindler K-LG, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 18:1177–85.10.1158/1078-0432.CCR-11-0564
    1. Tabernero J, Lenz H-J, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol (2015) 16:937–48.10.1016/S1470-2045(15)00138-2
    1. Spindler K-LG, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, et al. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. Eur J Cancer (2015) 51:2678–85.10.1016/j.ejca.2015.06.118
    1. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med (2016) 8:346ra92.10.1126/scitranslmed.aaf6219
    1. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 486(7404):532–6.10.1038/nature11156
    1. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 21:795–801.10.1038/nm.3870
    1. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol (2015) 26:1715–22.10.1093/annonc/mdv177
    1. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 26:3213–21.10.1200/JCO.2007.15.8923
    1. Zhao R, Cai Z, Li S, Cheng Y, Gao H, Liu F, et al. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget (2017) 8:9293.10.18632/oncotarget.14065
    1. Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer (2015) 112:1306–13.10.1038/bjc.2015.88
    1. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2013) 59:252–60.10.1373/clinchem.2012.188557
    1. Denis JA, Patroni A, Guillerm E, Pépin D, Benali-Furet N, Wechsler J, et al. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. Mol Oncol (2016) 10:1221–31.10.1016/j.molonc.2016.05.009
    1. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res (2006) 66:6871–6.10.1158/0008-5472.CAN-05-4556
    1. Jackson PE, Kuang SY, Wang JB, Strickland PT, Muñoz A, Kensler TW, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis (2003) 24:1657–63.10.1093/carcin/bgg101
    1. Xia L, Li Z, Zhou B, Tian G, Zeng L, Dai H, et al. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals. Sci Rep (2017) 7:7526.10.1038/s41598-017-06106-1
    1. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 20:1472–8.10.1038/nm.3733
    1. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 371:2477–87.10.1056/NEJMoa1409405
    1. Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell (2017) 168:571–4.10.1016/j.cell.2017.01.030
    1. Travis WD, Weltgesundheitsorganisation, International Agency for Research on Cancer editors. WHO Classification of Tumours of Lung, Pleura, Thymus and Heart. 4th ed Lyon: International Agency for Research on Cancer; (2015).
    1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014: colorectal cancer statistics, 2014. CA Cancer J Clin (2014) 64:104–17.10.3322/caac.21220
    1. Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res (1996) 16:2279–84.
    1. Spindler K-LG. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta Oncol (2017) 56:7–16.10.1080/0284186X.2016.1253861
    1. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer (2004) 111:746–9.10.1002/ijc.20327
    1. Grossman R, Abel B, Angiuoli S, Barrett J, Bassett D, Bramlett K, et al. Collaborating to compete: blood profiling atlas in cancer (BloodPAC) consortium. Clin Pharmacol Ther (2017) 101:589–92.10.1002/cpt.666
    1. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol (2008) 27:415–21.10.1089/dna.2008.0744
    1. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta (2007) 1775:181–232.10.1016/j.bbcan.2006.10.001
    1. Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochim Biophys Acta (2016) 1865:266–74.10.1016/j.bbcan.2016.03.006
    1. Zanetti-Dällenbach R, Wight E, Fan AX-C, Lapaire O, Hahn S, Holzgreve W, et al. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res (2008) 28:921–5.
    1. Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett (2006) 243:64–70.10.1016/j.canlet.2005.11.027
    1. Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal (2012) 26:467–72.10.1002/jcla.21548
    1. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer (2009) 8:105.10.1186/1476-4598-8-105
    1. Bechmann T, Andersen RF, Pallisgaard N, Madsen JS, Maae E, Jakobsen EH, et al. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. J Cancer Res Clin Oncol (2013) 139:995–1003.10.1007/s00432-013-1413-5
    1. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 24:4270–6.10.1200/JCO.2006.05.9493
    1. Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SSV, et al. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus (2015) 4:265.10.1186/s40064-015-1071-y
    1. Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat (2014) 146:163–74.10.1007/s10549-014-2946-2
    1. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res (2013) 15:211.10.1186/bcr3446
    1. Ai B, Liu H, Huang Y, Peng P. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget (2016) 7:44583.10.18632/oncotarget.10069
    1. Mao C, Yuan J-Q, Yang Z-Y, Fu X-H, Wu X-Y, Tang J-L. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine (Baltimore) (2015) 94:e775.10.1097/MD.0000000000000775
    1. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 9:154–62.10.1097/JTO.0000000000000033
    1. Yung TKF, Chan KCA, Mok TSK, Tong J, To K-F, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 15:2076–84.10.1158/1078-0432.CCR-08-2622
    1. Dowler Nygaard A, Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep (2014) 31(2):969–74.10.3892/or.2013.2906
    1. Zhuang R, Li S, Li Q, Guo X, Shen F, Sun H, et al. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: a systematic review and meta-analysis. PLoS One (2017) 12:e0182562.10.1371/journal.pone.0182562
    1. Winawer S. Workgroup II: the screening process. UICC international workshop on facilitating screening for colorectal cancer, Oslo, Norway (29 and 30 June 2002). Ann Oncol (2005) 16:31–3.10.1093/annonc/mdi029
    1. Spindler K-LG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, et al. Cell-free DNA in metastatic colorectal cancer: a systematic review and meta-analysis. Oncologist (2017) 22(9):1049–55.10.1634/theoncologist.2016-0178
    1. Wong A, Lim J, Sinha A, Gopinathan A, Lim R, Tan C-S, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med (2015) 13:57.10.1186/s12967-015-0405-4
    1. Basnet S, Zhang Z, Liao W, Li S, Li P, Ge H. The prognostic value of circulating cell-free DNA in colorectal cancer: a meta-analysis. J Cancer (2016) 7:1105–13.10.7150/jca.14801
    1. Diaz LA, Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 486(7404):537–40.10.1038/nature11219
    1. Shaw JA, Stebbing J. Circulating free DNA in the management of breast cancer. Ann Transl Med (2014) 2:3.10.3978/j.issn.2305-5839.2013.06.06
    1. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 4:136ra68.10.1126/scitranslmed.3003726
    1. Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, et al. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One (2015) 10:e0136407.10.1371/journal.pone.0136407
    1. Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol (2017) 117:38–47.10.1016/j.critrevonc.2017.07.003
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, O’callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 359:1757–65.10.1056/NEJMoa0804385
    1. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med (2015) 21:560–2.10.1038/nm.3854
    1. Paweletz CP, Sacher A, Raymond CK, Alden RS, O’Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res (2015) 22(4):915–22.10.1158/1078-0432.CCR-15-1627-T
    1. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking Genomic Cancer (2014). Available from:
    1. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med (2017) 376:2109–21.10.1056/NEJMoa1616288
    1. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol (2017) 10:100.10.1186/s13045-017-0468-1
    1. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov (2016) 6:147–53.10.1158/-15-1283
    1. Watanabe S. The metastasizability of tumor cells. Cancer (1954) 7:215–23.10.1002/1097-0142(195403)7:2<215::AID-CNCR2820070203>;2-6
    1. Fidler IJ. The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer (2003) 3:453–8.10.1038/nrc1098
    1. Li Y, Wu S, Bai F. Molecular characterization of circulating tumor cells – from bench to bedside. Semin Cell Dev Biol (2017).10.1016/j.semcdb.2017.09.013
    1. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 19:1450–64.10.1038/nm.3391
    1. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 17:1359–70.10.1038/nm.2537
    1. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 430:1034–9.10.1038/nature02765
    1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer (2004) 4:448–56.10.1038/nrc1370
    1. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 158:1110–22.10.1016/j.cell.2014.07.013
    1. Mohan S, Chemi F, Brady G. Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer. Transl Lung Cancer Res (2017) 6:454–72.10.21037/tlcr.2017.06.04
    1. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol (2016) 10:374–94.10.1016/j.molonc.2016.01.007
    1. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol (2006) 33:9–14.10.1053/j.seminoncol.2006.03.016
    1. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14:6302–9.10.1158/1078-0432.CCR-08-0872
    1. Gallo M, De Luca A, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, et al. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl Lung Cancer Res (2017) 6:486–98.10.21037/tlcr.2017.05.07
    1. Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures J-P, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 59:1384–92.10.1373/clinchem.2013.202846
    1. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 18:5701–10.10.1158/1078-0432.CCR-12-1587
    1. Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol (2014) 15:406–14.10.1016/S1470-2045(14)70069-5
    1. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2015) 33:2695–704.10.1200/JCO.2015.61.1459
    1. Pierga J-Y, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res (2004) 10:1392–400.10.1158/1078-0432.CCR-0102-03
    1. Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin Transl Oncol (2016) 18:322–30.10.1007/s12094-015-1372-1
    1. Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG, et al. Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res (2015) 21:2771–9.10.1158/1078-0432.CCR-14-2781
    1. Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 30:525–32.10.1200/JCO.2010.33.3716
    1. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett (2013) 335:225–31.10.1016/j.canlet.2013.02.015
    1. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th ed New York, NY: John Wiley & Sons; (2011).
    1. Brierley J, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 8th ed Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons, Inc; (2017).
    1. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin (2017) 67:290–303.10.3322/caac.21393

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir